News for Spectrum Pharma Stock (SPPI)

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 12/19/22

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI

Newsfile Corp • 12/17/22

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI

Newsfile Corp • 12/16/22

SPPI INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI

PRNewsWire • 12/14/22

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI

PRNewsWire • 12/13/22

SPPI EQUITY NOTICE: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

Business Wire • 12/13/22

Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate

PRNewsWire • 12/12/22

Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.

Business Wire • 12/12/22

National Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug Application

PRNewsWire • 12/09/22

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)

Business Wire • 12/06/22

SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

Business Wire • 12/06/22

Spectrum Pharmaceuticals' ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Business Wire • 12/06/22

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI

PRNewsWire • 12/06/22

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Zacks Investment Research • 11/28/22

U.S. FDA declines to approve Spectrum's lung cancer drug

Reuters • 11/25/22

Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Business Wire • 11/25/22

Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Call Transcript

Seeking Alpha • 11/11/22

Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Business Wire • 11/10/22

Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update

Business Wire • 11/03/22

ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - SPPI

PRNewsWire • 10/31/22

EQUITY ALERT: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – SPPI

Business Wire • 10/28/22

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection

Business Wire • 10/21/22

SPECTRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm

Business Wire • 09/30/22

Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

Zacks Investment Research • 09/26/22

Spectrum's stock is down after FDA committee voted against cancer drug

Market Watch • 09/23/22